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Implication for health policy/practice/research/medical education: {#key1}
==================================================================

In a study on 80 chronic renal failure patients not yet on dialysis with mean age of 59.82 ± 14.49 years, and serum level of fibroblast growth factor-23 (FGF23) of 15.028 ± 20.20 RU/ml, we found relationships of FGF23 with serum albumin (negative significant correlation) and systolic blood pressure (positive and significant).

Introduction {#s1}
============

The mortality rates in patients with chronic renal failure are higher than the others. Around 50% of these patients die as a result of cardiovascular disease conditions such as pulmonary edema, chronic heart failure, fatal arrhythmias, pericarditis, valvular disease and cardiogenic shock are some of cardiovascular disorders (CVD), as the leading cause of death in these patients. This can be probably due to a higher prevalence of important risk factors such as hypertension, anemia, uremia, disturbances in calcium, phosphorous and sodium, balance, dyslipidemia, atherosclerosis, diabetes mellitus and smoking. Chronic kidney disease (CKD) has been known as a serious condition which has significant complication. CKD is known as a risk factor of disorders such as cardiovascular diseases, electrolyte disturbances, bone disease, cognitive and psychological disorders and many other disease. The nature of this disease is progressive which causes new complications too. On the other hand, there are various parameters which can significantly affect the progress and complications of CKD ([@R1]-[@R4]).

Terminal stage of chronic renal failure named end-stage renal disease (ESRD). At this stage, patients will need renal replacement therapy. In ESRD patients have lower life expectancy and life quality than general population. Overall mortality rates in these patients are significantly higher than general population. Dialysis and kidney transplantation are two common methods of renal replacement therapy. Availability of the two methods, dialysis quality and support quality for kidney transplantation patients are factors which are strongly related to socio-economic conditions, health care facilities and health care constitutions of the society ([@R5]).

Objectives {#s2}
==========

In this investigation, we studied the correlation of serum levels of FGF23 with serum lipid profile, BMI and some of the other cardiovascular risk factors in a group of patients with CKD not yet on dialysis.

Patients and Methods {#s3}
====================

Study population {#s3-0-1}
----------------

This is a cross-sectional study which was conducted on 80 non-dialysis patients (glomerular filtration rate \[GFR\] \<60 cc/min) with CKD.

Data collection {#s3-0-2}
---------------

Patients' demographic information and medical history of the study population including age, sex, height, weight, history of smoking, heart disease, hypertension, diabetes, hyperlipidemia and drug history were obtained and recorded in pre-defined data sheets. Blood pressure of the patients were recorded. Laboratory measurements including serum levels of creatinine, triglyceride, total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), Apo A, Apo B, fasting blood sugar (FBS), serum levels of calcium, phosphorous, magnesium, alkaline phosphatase, intact parathyroid hormone (iPTH), 25-hydroxyvitamin D level, uric acid and albumin were measured after 12 hours fasting before obtaining their blood specimens, using standard kits. Serum FGF23 was assessed by ELISA method (Demeditec, Germany). Waist girth measured and body mass index (BMI) was also calculated by standard method (NIH).

Exclusion criteria {#s3-0-3}
------------------

The exclusion criteria were using steroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or estrogens. Also presence of active or chronic infection and malignancies were the other exclusion criteria.

Ethical issues {#s3-0-4}
--------------

The research followed the tenets of the Declaration of Helsinki. Informed consent was obtained and the research was approved by the Ethics Committee of Tehran University of Medical Science (Shariati hospital).

Statistical analysis {#s3-0-5}
--------------------

Quantitative variables were calculated as mean ± standard deviation (SD). *T* test and Mann-Whitney U test was used for analyzing the serum levels of qualitative variables and chi-square and Fisher's exact test for quantitative variables. *P* value lower than 0.05 was considered statistically significant. The distribution of quantitative data were assessed by one sample Kolmogorov--Smirnov test. Since FGF23 had not a normal distribution, Spearman's correlation was used for the relation to quantitative variables. Statistical analysis was conducted by SPSS version 18.

Results {#s4}
=======

This study included 44 men (55%) and 36 women. The mean age of patients was 59.82±14.49 years.

Cause of CKD among the patients were hypertension 34 (41%), diabetes mellitus 18 (21.7%), glomerulonephritis 10 (12%), renal stones 4 (4.8%), cysts 2 (2.4%) and unknown 15 (18%) ([Table 1](#T1){ref-type="table"}). The mean, SD, minimum and maximum of all variables and correlation of FGF23's variables are shown in [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. Mean ± SD of serum creatinine and FGF23 were 2.18±0.73 mg/dl and 15.028±20.20 RU/ml respectively. [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"} also show the association between FGF23 and other demographic or laboratory parameters. Briefly, correlation of FGF23 with age (*P*=0.55), serum creatinine (*P*=0.19), LDL-C (*P*=0.063), HDL-C (*P*=0.168) and serum triglyceride levels (*P*=0.99) was not significant. Likewise, the association of FGF23 serum with serum cholesterol (*P*=0.63), Apo A (*P*=0.21), and Apo B (*P*=0.74) was not significant. Accordingly, the correlation of FGF23 with intact PTH was not significant (*P*=0.28) ([Table 3](#T3){ref-type="table"}). The correlation between GFR of all patients (37.59±11.21 cc/min) and serum FGF23 was not significant (*P*=0.11). We categorized GFR into three groups in patients with following prevalence. Group 1 with GFR of 45-59 = 24 cc/min (29.6%), group two with GFR of 30-44 = 34(42%) and group 3 with GFR of 15-29 cc/min = 22 (27.2%). None of the groups had correlation with FGF (*P*\>0.05; [Table 4](#T4){ref-type="table"}).

###### Causes of chronic kidney disease

  -------------------- -----------
  **Causes**           **n (%)**
  Hypertension         34 (41)
  Diabetes mellitus    18 (21.7)
  Glomerulonephritis   10 (12)
  Renal stones         4 (4.8)
  Cysts                2 (2.4)
  Unknown              15 (18)
  -------------------- -----------

###### Data of the patients

  ----------------------------- --------------- ---------- ----------
  **Variable**                  **Mean ± SD**   **Min.**   **Max.**
  FGF23 (Ru/ml)                 15.028±20.20    0.20       103.40
  Age (y)                       59.82±14.49     24         83
  BMI, kg/m^2^                  27.58±5.84      17.6       40.5
  Waist girth (cm)              96.84±13.48     62         130
  FBS (mg/dl)                   105.73±32.68    50         212
  GFR (cc/min)                  37.59±11.21     6.2        59
  Creatinine (mg/dl)            2.18±0.73       1.1        5
  LDL (mg/dl)                   107.40±37.58    40         230
  HDL (mg/dl)                   42.56±20.20     18         167
  TG (mg/dl)                    180.66±100.24   51         751
  Cholesterol (mg/dl)           181.16±47.46    71         331
  Apo A (g/l)                   1.43±0.30       0.6        2.4
  Apo B (g/l)                   0.90±0.24       0.4        1.7
  iPTH (pg/ml)                  123.70±145.58   11.50      835
  Albumin (g/dl)                4.20±44.00      2.8        5
  Calcium (mg/dl)               9.01±0.84       5.4        12
  Magnesium (mg/dl)             2.27±0.33       1.1        3
  Phosphorous (mg/dl)           3.96±0.93       2.10       7.20
  Alkaline phosphatase (IU/l)   246.92±156.66   64         972
  Uric acid (mg/dl)             7.46±1.66       4          12.40
  BUN (mg/dl)                   81.82±39.74     27         281
  25-hydroxyvitamin D (ng/ml)   29.95±18.85     3.7        70
  SBP (mm Hg)                   132.00±15.23    110        190
  DBP (mm Hg)                   79.94±5.98      65         100
  ----------------------------- --------------- ---------- ----------

Abbreviations: FGF23, Fibroblast growth factor 23; iPTH, Intact parathyroid hormone; TG, Triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; FBS, fasting blood sugar; BMI, body mass index; BUN, blood urea nitrogen; SBP, diastolic blood pressure; DBP, diastolic blood pressure.

*P*\< 0.05 is considered significant.

###### Correlation and significant levels between FGF23 and variables

  ----------------------------- ---------------------- -------
  **Variables**                 **Correlation rate**   **P**
  FGF23 (Ru/ml)                                        
  Age (y)                       0.067                  0.55
  BMI (Kg/m^2^)                 -0.036                 0.75
  Waist girth (cm)              0.15                   0.18
  FBS (mg/dl)                   -0.019                 0.87
  GFR (cc/min)                  0.18                   0.11
  Creatinine (mg/dl)            0.14                   0.19
  LDL (mg/dl)                   -0.054                 0.63
  HDL (mg/dl)                   -0.156                 0.163
  Triglyceride (mg/dl)          -0.001                 0.99
  Cholesterol (mg/dl)           -0.53                  0.63
  Apo A (g/l)                   -0.14                  0.21
  Apo B (g/l)                   -0.038                 0.74
  IPTH (pg/ml)                  -0.12                  0.28
  Albumin (g/dl)                -0.23                  0.036
  Calcium (mg/dl)               0.006                  0.96
  Magnesium (mg/dl)             -0.1                   0.37
  Phosphorous (mg/dl)           -0.03                  0.78
  Alkaline phosphatase (IU/L)   0.038                  0.74
  Uric acid (mg/dl)             -0.064                 0.57
  BUN (mg/dl)                   -0.073                 0.51
  25-hydroxyvitamin D (ng/ml)   -0.19                  0.33
  SBP (mm Hg)                   0.41                   0.001
  DBP (mm Hg)                   0.18                   0.11
  ----------------------------- ---------------------- -------

Abbreviations: FGF23, Fibroblast growth factor 23; iPTH, Intact parathyroid hormone; TG, Triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; FBS, fasting blood sugar; BMI, body mass index; BUN, blood urea nitrogen; SBP, diastolic blood pressure; DBP, diastolic blood pressure.

###### Mean, SD and correlation of GFR to FGF23

  --------- ---------- ---------- ------------------ --------------------------- ---------
  **GFR**   **Min.**   **Max.**   **Mean** ±**SD**   **Pearson's correlation**   ***P***
  45-59     0.70       91.90      12.62±17.87        0.11                        0.65
  30-44     0.20       40.70      11.44±9.90         0.02                        0.43
  15-29     0.20       103.40     21.72±28.03        0.12                        0.21
  --------- ---------- ---------- ------------------ --------------------------- ---------

In this study, the association of FGF23 with systolic blood pressure was positively significant (r=0.41, *P*=0.001, [Table 4](#T4){ref-type="table"}) and also with serum albumin (r=-0.23, *P*=0.036) was negatively significant.

Discussion {#s5}
==========

Vitamin D and PTH have traditionally believed as the main factors in bone and mineral hemostasis, however, recent findings regarding FGF23 and bone-kidney have produced a new point of view in CKD and mineral bone disease. In summary, the most important function of vitamin D and PTH is stabilization of serum calcium levels in a suitable range through induction of 1,25-dihydroxy vitamin D \[1,25 (OH)2 D3\] synthesis, leading to reabsorption of calcium and reducing urinary excretion of calcium by kidneys. On the other hand, PTH also increase calcium uptake from bones.

PTH induces production of 1, 25 (OH) ~2~ D~3~ through increasing CYP27b1, increasing reuptake of calcium in proximal tubules and in distal tubules by regulation of TRPV5. Furthermore, PTH increases the uptake of calcium and phosphate in bones through inducing RANKL by osteoblasts (which in turn stimulate osteoclasts that increase uptake from bones). Additionally, increase of 1,25 (OH)~2~ D~3~ production by kidneys, causes an increase in phosphate and calcium reabsorption by small intestine. Overall, uptake of calcium from bones, decreases in urinary excretion of calcium and increases in its absorption by intestine results to normalizing serum calcium levels. Increasing the uptake of phosphate from bones and by intestines is regulated by PTH and reduces the reuptake of phosphate in renal tubules to balance the levels of phosphate. In fact, FGF23 and bone-kidney axis act as a biological route which have recently been discovered as the main players in CKD-mineral and bone disorder (CKD-MBD). Recent findings showed that osteoblasts and osteocytes are important sites for FGF23 production. FGF23 is excreted by bone, targets kidneys, and regulates phosphate and also vitamin D metabolism. It may also have other functions in regulating parathyroid and phosphate which needs to be studied further ([@R6]-[@R8]). In this study, we assessed the correlation of serum levels of FGF23 and BMI and lipid profile in patients with CKD. We studied 44 men (55%) and 36 women (45%). The mean age of patients was 59.82±14.49 years and the mean of FGF23 levels was 15.028±20.20 RU/ml. The correlations of FGF23 with BMI, LDL-C, HDL-C, Apo A, Apo B, triglyceride and cholesterol were not significant. Our study also showed that correlations between FGF23 and other factors such as age, sex, calcium, phosphorous and vitamin D were not significant. Our findings are opposed to the study of Mirza et al, which serum levels of triglyceride and total cholesterol positively correlated with serum FGF23. They also found an inverse relationship between Apo A1 and FGF23 ([@R9]). The study of Mirza et al showed that the correlation among FGF23 serum levels and BMI and waist girth is stronger than elevation of triglyceride and reduction of HDL-C, Apo A1. They also found that, serum FGF23 were correlated to trunk obesity and total body fat which may reveal a relation between cardiovascular disease and chronic renal failure to the level of FGF23 ([@R9]).

Holeck et al showed a correlation between FGF23 and metabolic syndrome in another study. They detected serum value of FGF23 was high in obese and premenopausal women. They concluded that, FGF23 is probably related to the reduction of serum phosphorous in obese patients ([@R10]). In animal studies, FGF23 has caused both vascular calcification and glucose and lipid homeostasis disturbances ([@R11]). It was also shown that phosphorus reducing therapy with sevelamer in chronic renal failure resulted in lipid improvement including elevation in HDL-C and reduction in LDL-C which can show a relation between bone metabolism and dyslipidemia in CKD. Other families of FGF such as FGF21 have higher levels in obesity, type 2 diabetes and metabolic syndrome ([@R11]). In the end-stages of CKD, FGF23 could not reduce serum phosphate and it seems that abnormally high plasma levels of FGF23 cause adverse effects such as LVH, rapid progression of CKD and early mortality ([@R12]).

Conclusion {#s6}
==========

In our study, only level of blood pressure and serum albumin levels were significantly correlated with FGF23. These require further investigation to better understand of this aspect of CKD patients.

Limitations of the study {#s7}
========================

Small proportion of the patients was a limitation of our investigation. Our study was cross-sectional and we could not compare our findings with a control group. Hence, it is suggested to conduct case-control studies with larger sample sizes to better assess the role of FGF23 in renal disease more precisely.
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